W. Bradford Smith
CIK: 0001317678
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Lyra Therapeutics, Inc.
Discretionary Trading P&L
Holdings
W. Bradford Smith files insider reports with the SEC as Director of Lyra Therapeutics, Inc. (LYRA). Signal8 holds 2 reported Form 4/5 transactions by W. Bradford Smith since Sep 2024. The most recent reported transaction is a disposition to issuer (Form 4 code D) in LYRA, dated May 14, 2026.
About Smith W Bradford
Smith W Bradford (SEC CIK 0001317678) files insider reports with the SEC as Director of Lyra Therapeutics, Inc. (LYRA).
Signal8 holds 2 ownership filings by Smith W Bradford, all Form 4s, filed between May 16, 2025 and May 15, 2026. Those filings report 2 transactions, from May 14, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith W Bradford's filings is in WATERTOWN, MA.
Recent filings by Smith W Bradford
Other insiders filing for Lyra Therapeutics, Inc. (LYRA)
- Palasis Maria, Principal Executive Officer
- Cavalier Jason, Principal Financial Officer
- PERCEPTIVE ADVISORS LLC, 10% Owner
- MERRIFIELD C ANN, Director
- TOBIN JAMES R, Director
- snyderman nancy lynn MD, Director